Dishman Carbogen Amcis Q1 FY27: Revenue Drops 4.3% to ₹677.6 Crore
Dishman Carbogen Amcis reported Q1 FY27 revenue of ₹677.6 crore, down 4.3% YoY due to CDMO revenue deferment. Marketable Molecules revenue grew 48%. EBITDA margin fell to 8.9% from 19.9%. The company posted a Q1 FY27 net loss of ₹578.8 crore.
The substantial decrease in revenue, sharp decline in profitability (resulting in a net loss), and reduced EBITDA margins are material financial events that are likely to have a significant impact on investor sentiment and the company's stock price.
The company reported a significant year-on-year decline in revenue and a substantial drop in EBITDA margins, leading to a net loss for the quarter. This indicates a negative financial performance for the period.
Dishman Carbogen Amcis Limited has announced its un-audited financial results for the quarter ended June 30, 2026. The company reported a net revenue of ₹6,776 million (₹677.6 crore) for Q1 FY27, a decrease of 4.3% compared to ₹7,080 million (₹708.0 crore) in Q1 FY26. This decline was primarily attributed to the deferment of Contract Development and Manufacturing Organisation (CDMO) revenue, partly offset by growth in the Marketable Molecules (MM) segment.
The CDMO revenue saw a year-on-year decline of 12.6%, mainly due to customer-requested rescheduling of project deliverables worth approximately CHF 10 million to the second half of the financial year. Conversely, revenue from the Marketable Molecules (MM) segment increased by 48% in Q1 FY27 compared to the same period in the previous year, driven by higher Cholesterol revenue.
EBITDA margins stood at 8.9% in Q1 FY27, a significant drop from 19.9% in Q1 FY26. The CDMO segment margin decreased to 6.3% from 17.9%, largely due to the deferment of revenues while the cost base remained largely fixed. A notional foreign exchange loss of ₹117.3 million also impacted the margins. The MM segment margin declined to 18.6% from 32.4%, primarily due to a higher proportion of Cholesterol sales compared to Vitamin D Analogues, although these margins are in line with full-year FY26 levels.
Profit Before Tax (PBT) for the quarter was a loss of ₹512.2 million, compared to a profit of ₹386.7 million in Q1 FY26. Consequently, the Profit After Tax (PAT) was a loss of ₹578.8 million, a significant decrease from a profit of ₹234.1 million in the corresponding quarter of the previous year. The PAT margin stood at -8.5% for Q1 FY27.
Capital expenditure during Q1 FY27 amounted to CHF 4.9 million. The net debt, excluding lease liabilities, was CHF 153.6 million as of June 30, 2026, an increase from CHF 146.8 million as of March 31, 2026.
The company also provided an investor presentation detailing its business overview, historical performance, and industry outlook. Dishman Carbogen Amcis is a fully integrated CDMO company with global operations and capabilities spanning process research and development to commercial manufacturing. The presentation highlighted its strengths in areas like ADC & Bioconjugation, robust R&D capabilities, and integrated services across the value chain. The industry outlook suggests continued growth in therapy areas like Oncology.
What to do with a filing like this
Dishman Carbogen Amcis Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dishman Carbogen Amcis Limited. Read the original for the full detail.